Human NEFL (Neurofilament, Light Polypeptide) ELISA Kit
- Known as:
- Human NEFL (Neurofilament, Light Polypeptide) Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- e-el-h0741
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Elabscience
- Gene target:
- Human NEFL (Neurofilament Light Polypeptide) ELISA Kit
Related genes to: Human NEFL (Neurofilament, Light Polypeptide) ELISA Kit
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: Human NEFL (Neurofilament, Light Polypeptide) ELISA Kit
Related articles to: Human NEFL (Neurofilament, Light Polypeptide) ELISA Kit
- Amyotrophic lateral sclerosis (ALS) likely has a prolonged presymptomatic phase. Identifying blood biomarkers that predict phenoconversion is critical for early intervention. - Source: PubMed
Publication date: 2026/09/03
Lehrer StevenRheinstein Peter H - Ischemic stroke is a leading cause of death and disability worldwide. Although advances in interventions for acute ischemic stroke (AIS) restore blood flow to ischemic tissue, neuronal injury continues to evolve following recanalization. There is a critical need to develop interventions that can attenuate this progressive injury. This study investigated plasma neurofilament light chain (NfL) as a marker of neuroaxonal damage after AIS. In a prospective, randomized, open-label, blinded-endpoint, sham-controlled trial, 35 AIS patients received twice-daily taVNS or sham stimulation for five days or until discharge. We measured NfL at four time points after last known normal (LKN): Days 0 (within 24 h), 1, 3, and 5. We evaluated whether transauricular vagus nerve stimulation (taVNS) modulates its dynamics after AIS. Plasma NfL level continued to increase during the acute and early subacute periods following AIS. Higher NfL levels predicted poorer modified Rankin Scale scores at day 90. We identified factors that affect NfL levels, including imaging-based measures of cerebral edema and infarct volume, race, IL-10 at admission, and thrombolytic treatment. After regressing NfL on the identified factors, treatment assignment was not significantly associated with overall NfL levels. Nevertheless, NfL-trajectory modeling suggested that taVNS was associated with a less pronounced rise in NfL after AIS and with significantly lower NfL levels on Days 3 and 5 after LKN, compared with sham stimulation. Our findings inform the clinical use of NfL as a biomarker of long-term functional recovery after AIS and warrant evaluation in larger and longer trials to determine whether taVNS can meaningfully mitigate neuroaxonal injury after AIS.Trial registration: NCT05390580, https://clinicaltrials.gov/study/NCT05390580-Study started/registered: 26/09/2022. - Source: PubMed
Publication date: 2026/08/31
Tan GanshengLaurido-Soto Osvaldo JHuguenard AnnaDhar RajatLee Jin-MooLeuthardt Eric - Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are biomarkers of neuroaxonal and astrocytic damage but remain understudied in adolescent psychiatric populations. This study investigated sNfL and GFAP levels in 412 adolescents diagnosed with anorexia nervosa (AN) (n = 52), depression (n = 237), and other psychiatric disorders (n = 123). We assessed their diagnostic utility, correlation with disease severity, and longitudinal changes during AN treatment. Biomarkers were measured using Single Molecule Array technology, with Z-scores derived from reference datasets. Compared to population norms, both biomarkers were elevated in AN (sNfL: 1.15 ± 1.17; GFAP: 1.50 ± 0.84) and in depression (sNfL: 0.34 ± 1.10; GFAP: 0.58 ± 1.00). Patients with AN showed significantly higher biomarker levels than those with depression or other psychiatric disorders; importantly, this distinction remained evident in sensitivity analyses restricted to underweight individuals with depression. In AN, sNfL levels correlated with baseline weight loss (β = -0.45, R² = 0.20) and declined significantly during treatment, while GFAP changes were less pronounced. Neither marker correlated with depressive symptom severity. Bootstrapped ROC analyses showed moderate-to-good discriminatory power (AUCs 0.70-0.84) for distinguishing AN from depression. These findings suggest that neuroaxonal and astrocytic stress is a component of adolescent psychopathology, particularly in AN. sNfL appears sensitive to starvation-related neurobiological changes, with levels normalizing alongside weight restoration. GFAP showed similar but less robust trends. Accordingly, the observed biomarker changes reflect more than underweight alone, supporting a potential role in differential diagnosis and treatment monitoring. - Source: PubMed
Publication date: 2026/08/26
Pawlitzki MarcMasanneck LarsSchlarbaum LauraJankovic NicoleBittner StefanSteffen FalkKuhle JensBenkert PascalRepple JonathanBühlmeier JudithHinney AnkeHebebrand JohannesHirtz RaphaelG Meuth SvenLibuda LarsFöcker Manuel - Blood-based and diffusion MRI (dMRI) biomarkers of white matter injury after acute mild traumatic brain injury (mTBI) were examined to: (1) distinguish mTBI from healthy controls (HC); (2) quantify inter-modality relationships; (3) identify associations between acute biomarker changes and recovery; (4) evaluate moderating influences of resilience and coping style. - Source: PubMed
Publication date: 2026/08/25
Papini Melissa GThorne JacintaGozt Aleksandra KAvila Andre N CEllery Caerwen SGilroy RubyGill GeenaBuhagiar FrancescaThomas ElizabethArmstrong AmandaPedrini SteveTaddei KevinMartins Ralph NRing AlexanderArendts GlennCelenza AntonioIliff John CharlesXu DanHoneybul StephenCowen GillSmedley BenFatovich DanielBynevelt MichaelPestell CarmelaFitzgerald MelindaHellewell Sarah C - Wild-type transthyretin amyloidosis (ATTRwt) is a progressive disease marked by extracellular transthyretin amyloid deposition, predominantly causing cardiomyopathy. Neurological manifestations are known in hereditary ATTR but remain comparatively understudied in ATTRwt. - Source: PubMed
Publication date: 2026/08/25
Kleinveld Vera E AWanschitz JuliaHotter AnnaUngericht MariaSanders PetraPölzl GerhardFanciulli AlessandraLöscher Wolfgang NHorlings Corinne G C